180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics. 180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics.
PALO ALTO, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (“180” or the “Company”) is pleased to announce the appointment of Omar Jimenez as its new Chief Financial Officer...
PALO ALTO, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- PALO ALTO, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today...
PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that it received notice from the Nasdaq...
PALO ALTO, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that it received notice from the Nasdaq...
PALO ALTO, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the Company received a letter on March...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.074 | 4.04371584699 | 1.83 | 2.65 | 1.66 | 65143 | 2.24666237 | CS |
4 | 0.214 | 12.6627218935 | 1.69 | 4.8 | 1.46 | 634564 | 2.81617466 | CS |
12 | -1.666 | -46.6666666667 | 3.57 | 4.8 | 1.31 | 365839 | 2.65562423 | CS |
26 | -7.976 | -80.7287449393 | 9.88 | 15.7168 | 1.31 | 528733 | 4.12559621 | CS |
52 | -106.396 | -98.241920591 | 108.3 | 135.8481 | 1.31 | 837871 | 48.5721493 | CS |
156 | -197.216 | -99.0437926878 | 199.12 | 247.8607 | 1.31 | 843359 | 75.40549743 | CS |
260 | 0 | 0 | 0 | 2.09 | 0 | 0 | 0 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約